Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

NeuShen and UMass Partner To Develop Gene Therapy for ALS

publication date: Feb 1, 2023

NeuShen Therapeutics, a Shanghai-Boston CNS biotech, announced a three-year Sponsored Research Agreement with UMass Chan Medical School to develop a gene therapy for amyotrophic lateral sclerosis (ALS). NeuShen is developing CNS therapies using its dual AAV-based gene and small molecule platforms. The program will be under the direction of Dr. Guangping Gao, PhD, a well-known gene therapy researcher who has played an important role in discovering and characterizing a new family of adeno-associated virus (AAV) serotypes, which has advanced gene therapy research for currently untreatable human diseases. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital